Cargando…
Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways
BACKGROUND: Factor Xa (FXa) not only plays an active role in the coagulation cascade but also exerts non-hemostatic signaling through the protease-activated receptors (PARs). This study aimed to investigate whether the FXa inhibitor, Rivaroxaban (RIV), attenuates adverse cardiac remodeling in rats w...
Autores principales: | Zhang, Qian, Zhang, Zhongfan, Chen, Weiwei, Zheng, Haikuo, Si, Daoyuan, Zhang, Wenqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541813/ https://www.ncbi.nlm.nih.gov/pubmed/37786576 http://dx.doi.org/10.7717/peerj.16097 |
Ejemplares similares
-
Rivaroxaban in heart failure patients with left ventricular thrombus: A retrospective study
por: Zhang, Qian, et al.
Publicado: (2022) -
Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021) -
Clinical profile and prognosis of elderly patients with left ventricular thrombus after anticoagulation
por: Zhang, Qian, et al.
Publicado: (2023) -
Value of the platelet-to-lymphocyte ratio in the prediction of left ventricular thrombus in anterior ST-elevation myocardial infarction with left ventricular dysfunction
por: Zhang, Qian, et al.
Publicado: (2020) -
RUNX1 facilitates heart failure progression through regulating TGF-β-induced cardiac remodeling
por: Qi, Peng, et al.
Publicado: (2023)